Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab

To determine the clinical predictors of response rate, progression-free survival (PFS), and overall survival (OS) to pembrolizumab in advanced or recurrent, mismatch repair deficient (MMRd) or Microsatellite Instability-High (MSI-H) endometrial adenocarcinomas. A retrospective, single institution st...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2024-01, Vol.180, p.139-145
Hauptverfasser:	Bernard, Laurence, How, Jeffrey A., Patel, Shrina, Yates, Melinda S., Jazaeri, Amir
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - genetics Antibodies, Monoclonal, Humanized Brain Neoplasms Carcinoma - complications Colorectal Neoplasms DNA Mismatch Repair Endometrial cancer Endometrial Neoplasms - drug therapy Endometrial Neoplasms - genetics Female Humans Immunotherapy Microsatellite Instability Microsatellite Repeats Neoplastic Syndromes, Hereditary Obesity Obesity - complications Pembrolizumab Progression-Free Survival Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!